WuXi Biologics (Cayman) Inc. (HKG:2269)

WuXi Biologics Revenue

In the year 2024, WuXi Biologics had annual revenue of 18.68B CNY with 9.63% growth. WuXi Biologics had revenue of 10.10B in the half year ending December 31, 2024, with 25.29% growth.

• Revenue: 18.68B CNY
• Revenue Growth: +9.63%
• P/S Ratio: 5.70
• Revenue / Employee: 1.47M CNY
• Employees: 12,740
• Market Cap: 113.71B HKD

Revenue Chart

* This company reports financials in CNY.

Revenue History

Fiscal Year End	Revenue	Change	Growth
Dec 31, 2024	18.68B	1.64B	9.63%
Dec 31, 2023	17.03B	1.77B	11.56%
Dec 31, 2022	15.27B	4.98B	48.38%
Dec 31, 2021	10.29B	4.68B	83.35%
Dec 31, 2020	5.61B	1.63B	40.88%